Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ARRIS PHARMACEUTICAL's $ 8 MIL. IN FIRST-ROUND FINANCING

Executive Summary

ARRIS PHARMACEUTICAL's $ 8 MIL. IN FIRST-ROUND FINANCING is earmarked for three research projects for orally-active drugs for cardiovascular and pulmonary diseases. The firm, headed by former Genetech VP-Medicinal and Biomolecular Chemistry Michael Ross, PhD, was founded in May 1989 by C.W. Group venture capitalist Chuck Hartman. The seed round of financing raised $ 8 mil. for the startup, which combines researchers and advisors in the fields of molecular biology, cell biology, peptide chemistry, X-ray crystallography, applied mathematics and computational science. South San Francisco-based Arris is using artificial intelligence tools such as robotics, machine vision and machine learning to develop "new molecular shape representations and identify important structural patterns in those shapes," the firm said. A daily pill to treat atherosclerosis is the firm's initial product-development effort. Arris is also working on an oral replacement for erythropoietin and "a series of products in the pulmonary area." The atherosclorosis treatment is a collaborative project with Massachusetts Institute of Technology researchers to develop a macrophage scavenger receptor (MSR) inhibitor. The potential therapeutic would block the formation of "foam cells" -- formed when macrophages bind with "bad" low-density lipoprotein (LDL) cholesterol -- and the subsequent formation of artery-clogging plaque. An MSR inhibitor could be used in conjunction with cholesterol-lowering drugs, Arris noted. The R&D firm expects to sign up a corporate partner "within the next year," the company said. Arris initially plans to license worldwide rights to its products, with the eventual goal of retaining some rights for products in certain niche markets. In addition to Ross, who is president, CEO and chief technical officer, former Genetech employees now at Arris are Chief Financial Officer Mark Hirsch and Stanford University professor Richard Lawn, PhD. Hirsch was VP of business development at Genentech from 1985-88 and subsequently was a partner at Mongtomery Medical Ventures, L.P. II until 1991. Lawn, a molecular biologist who is professor of cardiovascular medicine at Stanford, spent 10 years at Genentech and ultimately was the company's senior scientist.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel